Pyxis Oncology: New Routes To Immuno-Oncology Therapies
Bayer’s VC LEAPS program invests in a second new biotech this month through its participation in the series A funding round for new immuno-oncology biotech Pyxis Oncology.
You may also be interested in...
Private Company Edition: Several drug developers targeting neurological diseases raised venture capital recently. In addition to Nura Bio, Encoded Therapeutics revealed a $135m series D round. Also, Longwood closed a $170m fund and Flagship launched Omega Therapeutics with $85m.
Private Company Edition: IPOs and M&A are returning money to investors, who are putting that money into new investments. Also, the mega-push in VC mega-rounds continues, including $105m for Kronos, and RA Capital raises it first VC fund.
With Bayer’s venture arm providing $215m, Versant Ventures’ Century Therapeutics emerges with $250m and a plan to develop allogeneic stem cell therapies for various cancers, including solid tumors.